A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Eli Lilly and Company
Study ID
NCT07258836
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy
  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • LY4214835 — DRUG
    Administered IV

Study Details

The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.

Key Dates

Start date
Dec 22, 2025
Status verified
Apr 2026
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
41 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4214835 (Cohorts 1 and 2)
    LY4214835 administered intravenously (IV)

Primary Outcome Measure

Number of Incidence of Adverse Events (AEs) [ Time Frame: Baseline Through Day 3 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (6)

FacilityCityStateZIPSite coordinators
InvicroNew HavenConnecticut06510-
Boston Medical CenterBostonMassachusetts02118-
Massachusetts General Hospital (MGH)CharlestownMassachusetts02129-
BAMF Health Inc.Grand RapidsMichigan49503-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Ichor ResearchSyracuseNew York13210-

Find similar trials in New Haven, CT

By research site
Invicro· New Haven, CTBoston Medical Center· Boston, MAMassachusetts General Hospital (MGH)· Charlestown, MABAMF Health Inc.· Grand Rapids, MIMemorial Sloan Kettering Cancer Center· New York, NYIchor Research· Syracuse, NY

Related Studies